Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
13.75 USD | +4.88% | +19.77% | +92.04% |
Financials (USD)
Sales 2023 * | 24.36M | Sales 2024 * | 142M | Capitalization | 1.23B |
---|---|---|---|---|---|
Net income 2023 * | -160M | Net income 2024 * | -40M | EV / Sales 2023 * | 50,7x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 8,72x |
P/E ratio 2023 * | -6,85x | P/E ratio 2024 * | -30,6x | Employees | 41 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 39.69% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +4.88% | ||
1 week | +19.77% | ||
Current month | +19.15% | ||
1 month | +26.38% | ||
3 months | +7.30% | ||
6 months | -4.51% | ||
Current year | +92.04% |
1 week
11.36
13.93

1 month
10.25
13.93

Current year
6.35
16.85

1 year
5.92
16.85

3 years
1.05
16.85

5 years
1.03
16.85

10 years
1.03
26.09

Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 56 | 2017 |
Thomas McHugh
DFI | Director of Finance/CFO | 58 | 2019 |
Scott Macke
COO | Chief Operating Officer | - | 2014 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 54 | 2018 |
Gregory Divis
CEO | Chief Executive Officer | 56 | 2017 |
Mark McCamish
BRD | Director/Board Member | 71 | 2019 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.54% | 4 M€ | -12.25% | - | |
0.53% | 5 M€ | -13.81% | ||
0.08% | 15 M€ | -5.88% | ||
0.08% | 329 M€ | -9.12% | ||
0.08% | 34 M€ | -5.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-05 | 13.75 | +4.88% | 1,368,893 |
23-12-04 | 13.11 | +4.63% | 881,320 |
23-12-01 | 12.53 | +8.58% | 808,127 |
23-11-30 | 11.54 | +1.14% | 291,772 |
23-11-29 | 11.41 | -0.61% | 230,301 |
Delayed Quote Nasdaq, December 05, 2023 at 04:00 pm EST
More quotes
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Sector
Pharmaceuticals
Calendar
2024-03-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy

Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.75USD
Average target price
20USD
Spread / Average Target
+45.45%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.04% | 1 235 M $ | |
+60.77% | 529 B $ | |
+46.50% | 444 B $ | |
-10.25% | 382 B $ | |
-4.25% | 269 B $ | |
-10.54% | 255 B $ | |
-13.61% | 231 B $ | |
+1.76% | 200 B $ | |
-9.57% | 198 B $ | |
-43.23% | 164 B $ |